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Abstract
Background Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel technique of intraperitoneal chemo-
therapy. First results obtained with PIPAC in patients with advanced peritoneal metastasis (PM) from gastric cancer
(GC) are presented.
Methods Retrospective analysis: Sixty PIPAC were applied in 24 consecutive patients with PM from GC. 67 % patients
had previous surgery, and 79 % previous platinum-based systemic chemotherapy. Mean Peritoneal Carcinomatosis Index
(PCI) of 16±10 and 18/24 patients had signet-ring GC. Cisplatin 7.5 mg/m2 and doxorubicin 1.5 mg/m2 were given for
30 min at 37 °C and 12 mmHg at 6 week intervals. Outcome criteria were survival, adverse events, and histological
tumor response.
Results Median follow-up was 248 days (range 105–748), and median survival time was 15.4 months. Seventeen patients had
repeated PIPAC, and objective tumor response was observed in 12 (12/24=50 %): no vital tumor cells=6, major pathological
response=6, minor response=3. Postoperative adverse events>CTCAE 2 were observed in 9 patients (9/24, 37.5 %). In 3/17
patients, a later PIPAC could not be performed due to non-access. Two patients (ECOG 3 and 4) died in the hospital due to disease
progression.
Conclusion PIPACwith low-dose cisplatin and doxorubicin was safe and induced objective tumor regression in selected patients
with PM from recurrent, platinum-resistant GC. First survival data are encouraging and justify further clinical studies in this
indication.
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Introduction
Gastric cancer is the second most common cause of death
from cancer worldwide.1 In most patients with gastric cancer,
therapy is palliative and systemic chemotherapy including 5-
FU/platinum combinations, with or without an anthracycline,
as well as irinotecan and docetaxel-containing combinations is
the current standard of care.2 Peritoneal carcinomatosis de-
velops in more than half of patients.3 These patients have a
poor prognosis with a median survival of 3–5 months without
treatment.4,5 No large-scale comparative studies document the
efficacy of systemic chemotherapy in gastric peritoneal me-
tastasis, but it appears to be modest.6
Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
is a novel technique delivering drugs into the abdominal cav-
ity as a aerosol under pressure. Taking advantage of physical
laws, it is generating an artificial pressure gradient enhancing
tissue uptake and distributing drugs homogeneously within
the closed and expanded abdominal cavity. Prior experimental
work has documented the favorable effects of applying pres-
sure into the peritoneal cavity,7–9 by counteracting the elevat-
ed intratumoral interstitial fluid pressure10 and enhancing drug
uptake by convection. PIPAC is a short laparoscopic proce-
dure and can be repeated. Only approved chemotherapeutic
drugs were applied so far so that a cytotoxic activity is expect-
ed after PIPAC application.
In an ex vivomodel of human peritoneal metastasis, PIPAC
resulted in a higher local concentration of a small molecule
(Dbait) compared to intraperitoneal lavage and in a deeper
tissue penetration.11 In the abdomen of pigs, PIPAC allowed
a homogeneous distribution of a staining agent as compared to
closed liquid circulation.12 Based on these encouraging data,
PIPAC was first applied in November 2011 in 3 end-stage
patients with peritoneal metastasis.13 Courses of PIPAC con-
taining cisplatin 7.5 mg/m2 and doxorubicin 1.5 mg/m2 (about
10 % of an usual systemic dose) at 12 mmHg and 37 °C for
30 min were applied q 28–42 days. The application was well
tolerated and superior pharmacological properties confirmed.
Intratumoral concentration of doxorubicin was much higher
(up to 2×102) than reported after HIPEC, with 10 % of the
usual dose. Systemic drug concentration remained low, and
PIPAC caused almost no hepatic and renal toxicity.14 No local
complication was recorded. However, a strong increase of C-
reactive protein was observed as a sign of the chemical peri-
tonitis. Regression of peritoneal nodules was observed in all
three patients, and a patient survived 2 years after first PIPAC.
In a retrospective case series of 18 women with recurrent
ovarian cancer, repeated courses q 28–42 days of PIPAC with
the same regimen were safe and effective when applied with-
out concomitant cytoreductive surgery. These results indicated
a PIPAC activity in women with recurrent, platinum-resistant
ovarian cancer.15 Recently, a regulatory prospective phase-2
trial with low-dose doxorubicin and cisplatin applied as a
pressurized aerosol in recurrent, platinum-resistant ovarian
cancer showed a clinical benefit rate (CBR) of 62 % and an
objective histological regression rate of 76 % coupled with a
low incidence of severe adverse events: 15 % CTCAE 3, no
CTCAE 4 and 5.16 Thus, PIPAC might become a new and
promising drug delivery technique for ovarian cancer patients
in the recurrent and perhaps also in the adjuvant setting.17,18
We now report about our first observations with low-dose
PIPAC application in patients with gastric peritoneal
metastasis.
Methods
In fall 2011, we opened a PIPAC program for patients diag-
nosed with advanced, therapy-resistant gastric peritoneal me-
tastasis. Therapy was conducted in accordance with the
Helsinki’s declaration. All patients gave their informed con-
sent. The Ethics Committees of the Ruhr University Bochum,
Germany expressed no objection. Access to this off-label use
program was limited to patients who had a life-threatening
disease, including some patients with advanced disease in
reduced general condition (ECOG 3 and 4) and with large
amount of ascites.
Prior to therapy, each patient was evaluated by the multi-
disciplinary tumor board at the Marien Hospital Herne, Ruhr-
University Bochum, Germany. There were no specific inclu-
sion or exclusion criteria, and therapeutic indication was indi-
vidual. All patients had histologically verified peritoneal me-
tastasis of gastric origin, no option for complete cytoreductive
surgery (CRS) and hyperthermic intraperitoneal chemothera-
py (HIPEC) because of poor general condition, signet cell
histology, advanced PCI, and/or diffuse small bowel involve-
ment. Most of them had previous palliative systemic chemo-
therapy. A few patients were medically unfit for systemic pal-
liative chemotherapy or refused to receive it. Patients with
other metastatic localization were not treated (with the excep-
tion of pleural effusion). Reduced general condition
(Karnofsky≤60%), therapy-resistant ascites, and partial small
bowel obstruction were not considered as exclusion criteria.
All interventions were performed under general anesthesia.
After insufflation of a 12 mmHg capnoperitoneum (with open
access or Veres needle), two trocars (5 and 12 mm, Kii®,
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Applied Medical, Düsseldorf, Germany) were inserted into
the abdominal wall. Ascites were removed. Extent of perito-
neal carcinomatosis was determined.19 Peritoneal biopsies
were taken in all 4 quadrants, and a centimetric local
peritonectomy was performed to improve accuracy of histo-
pathology, in particular when biopsies remained negative. A
micropump (MIP®, Capnomed, Villingendorf, Germany) was
connected to an intravenous high-pressure injector (Arterion
Mark 7®, Medrad, Germany) and inserted into the abdomen.
Tightness of the abdomen was documented via a zero flow of
CO2. The procedure was performed in a room equipped with
laminar air flow. A pressurized aerosol containing doxorubi-
cin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9 %
followed by cisplatin at a dose of 7.5 mg/m2 in a 150-ml NaCl
0.9 % was applied. Flow was 30 ml/min, and upstream pres-
sure was 200 psi. Injection was remote-controlled and nobody
remained in the room during application. The therapeutic
aerosol was maintained at 12 mmHg for 30 min at 37 °C.
Then, it was released safely via a Closed Aerosol Waste Sys-
tem (CAWS). Trocars were retracted and laparoscopy ended.
No drainage was applied.
Follow-up was obtained by telephone calls until
November 21st, 2013 or until death. All data were docu-
mented according to our institutional rules, including
electronic archiving and video recording of the proce-
dures. Histological tumor response was assessed by an
independent anatomopathologist. Adverse events were
graded according to the Common Terminology Criteria
for Adverse Events (CTCAE). Analysis was retrospective.
Survival was modelled in a Kaplan–Meier curve. We used
SPSS for Windows (v.20.0, SPSS Inc., Chicago, IL) for
analysis.
Results
A total of 25 consecutive patients were scheduled for PIPAC.
In one patient, access to the abdominal cavity was not possible
due to extensive adhesions (n=1/25; 4% primary non-access).
Twenty-four patients (M/F=12:12) with a mean age of 56
(±13) years received ≥1 PIPAC and are object of further anal-
ysis. Patient’s characteristics and preoperative details are sum-
marized in Table 1. Most tumors were classified as diffuse or
signet-ring cancers (18/24, 75 %), and peritoneal metastasis
was advanced (mean PCI of 16±10). Three patients had ma-
lignant pleural effusion, and liver metastasis was diagnosed at
PIPAC #2 in a further patient so that 4 patients had
extraperitoneal metastasis. Five patients (21 %) were in re-
duced general condition (ECOG>2); in 3 patients, systemic
chemotherapy was contraindicated. Most patients were pre-
treated: 19/24 (79 %) had previous (radio)chemotherapy, and
11 patients (46 %) were in the 3rd line or 4th line situation.
Fourteen patients (58 %) had previous gastrectomy; a further
patient had intestinal bypass surgery. Eight patients (33 %)
received PIPAC in combination with systemic chemotherapy.
A total of 60 successful PIPAC procedures were performed
in the 24 patients. Seventeen patients (71 %) had repeated
PIPAC (2 patients: 5 PIPAC, 5 patients: 4 PIPAC, 3 patients:
3 PIPAC, 7 patients: 2 PIPAC. In 3 patients, non-access of the
abdomen because of adhesions prevented repeated PIPAC ap-
plication (at 2nd, 3rd, and 6th intended PIPAC session). Mean
operating time was 91±34 min. Three intraoperative compli-
cations were noted (3/60, 5 %), including two bowel access
lesions that were repaired (CTCAE 2). One severe allergic
reaction to metamizol was controlled with corticoids and vol-
ume therapy.
PIPAC was well tolerated. Adverse events are summarized
in Table 2. Abdominal pain CTCAE ≤2 was noted in 6/24
patients (25 %). Elevated postoperative serum C-reactive pro-
tein was observed in most patients (16/24, 67 %) as a sign of
the chemical peritonitis (Fig. 1). A patient with biliary stent
developed postoperative cholangitis, another developed ery-
thema at an abdominal port site. In one case, upper gastroin-
testinal bleeding was suspected but not confirmed. No
procedure-related mortality was noted. Two patients in re-
duced general condition died in the hospital, one of them
(ECOG 4, ASA4, therapy-resistant ascites, and pre-existing
renal failure) because of lung edema after 1st PIPAC, and
the other patient (ECOG 3) because of progressive small
Table 1 Characteristics of 24 patients with PC from gastric origin
undergoing pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Variable Value
Number of patients 24
Sex (M/F) 12:12





Extraperitoneal metastasis 4 (17 %)
Pleura 3
Liver 1
Peritoneal Carcinomatosis Index (mean±SD) 16 (±10)
Karnofsky Index before first PIPAC (mean±SD) 78 (±22 %)
Previous organ surgery 15/24 (63 %)




Contraindication for chemotherapy 3
Patient refusal 2
Simultaneous chemotherapy 8 (33 %)
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bowel obstruction after 2nd PIPAC. In the first case, cardio-
pulmonary decompensation was explained by ascites removal
in a critically ill patient; in the second case, bowel obstruction
was explained by disease progression and bowel invasion. A
direct causal relationship with PIPAC (laparoscopy and appli-
cation of low-dose cisplatin and doxorubicin) was considered
to be unlikely.
Out of 24, a total of 17 patients having received ≥2 PIPAC
cycles were eligible for tumor response assessment. In 6 pa-
tients, no vital tumor cells were found (complete histological
remission); in 6 further patients, partial regression was docu-
mented and in three stable disease. Thus, in total, histological
response was confirmed in 50% (12/24) patients. Examples of
tumor regression are shown in Fig. 2 and Suppl. Material 1.
Median follow-up was 248 days (range 105–748). At the
end of follow-up, 13/24 patients were alive. Median survival
overall survival was 15.4 months. Overall survival after 1 year
was 52 %. Three out of 11 deaths occurred in patients with
extraperitoneal disease, with a median survival of 3.5 months
(Fig. 3).
Table 2 Adverse events
Patient Operation Response CTCAE grading Adverse event
1 2×PIPAC, small bowel resection CR 1 Abdominal pain
2 1×PIPAC N/A 1 CRP
3 4×PIPAC CR 1 CRP
4 1× PIPAC, ileostomy N/A 3 CRP, Cholangitis
5 4×PIPAC PR 3 Hepatotoxicity, abdominal pain
6 2× PIPAC SD 1 CRP
7 4× PIPAC PD 1 CRP
8 1× PIPAC N/A 1 Abdominal pain
9 5× PIPAC CR 1 Abdominal pain, CRP
10 5×PIPAC, adhesiolysis, incisional hernia repair CR 1 Hepatotoxicity, CRP
11 4× PIPAC PR 4 Allergy, myolysis
12 3× PIPAC, small bowel resection PR 3 Hepatotoxicity, abdominal pain
13 3× PIPAC CR 1 Abdominal pain, CRP
14 1× PIPAC N/A 1 CRP
15 2× PIPAC PR 1 CRP
16 2× PIPAC PR 1 N/V, CRP
17 3× PIPAC SD 1 Renal toxicity, CRP
18 2× PIPAC, gastrectomy CR 1 CRP
19 2× PIPAC PR 5 CRP, Hepatotoxicity, progressive SBO, death
20 1× PIPAC N/A 3 CRP, Hepatotoxicity
21 2× PIPAC PD 3 Hepatotoxicity
22 1× PIPAC N/A 5 Ascites decompensation, death
23 5× PIPAC SD 3 Hepatotoxicity, CRP, 2×Access lesion
24 1× PIPAC N/A 1 Access site extravasation
PIPAC pressurized intraperitoneal aerosol chemotherapy, CRS cytoreductive surgery, CTCAE Common Terminology Criteria for Adverse Events
Version 4.0, CR complete remission, PR partial remission, SD stable disease, PD progressive disease, CRP C-reactive protein, RT renal toxicity,
N/V nausea–vomiting, SBO small bowel obstruction
Fig. 1 PIPAC is well tolerated. Although the dose applied is only 10% of
a usual systemic dose, patients develop a postoperative inflammatory
syndrome with elevated C-reactive protein, probably explained by a
chemical peritonitis. However, acute and cumulative local toxicities of
PIPAC are well controlled and no bowel perforation and no
gastrointestinal side effects>CTCAE grade 2 were observed
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Discussion
In patients with cancer confined to the peritoneal cavity, there
is established pharmacokinetic evidence that intraperitoneal
drug administration is advantageous.20 Intraperitoneal chemo-
therapy may improve survival of patients with gastric perito-
neal metastasis.21 However, owing to the limited penetration
of chemotherapy into tumor nodules, intraperitoneal chemo-
therapy may be best suited for small volume disease.22
For treating larger lesions, it has been proposed to perform
a complete surgical cytoreduction prior to intraperitoneal
chemotherapy.23 In gastric cancer, combining cytoreductive
surgery with heated intraperitoneal chemotherapy (HIPEC)
allowed long-term survival in a selected group of patients with
limited peritoneal disease.24 However, this procedure has sig-
nificant complications with a 30-day mortality of 5 %.25
Moreover, pharmacokinetic problems such as poor tumor pen-
etration and incomplete irrigation of serosal surfaces limit the
effectiveness of HIPEC.26 Thus, the benefit of adding HIPEC
to cytoreductive surgery might be only marginal26 and its role
in gastric cancer remains a matter of debate,27 in particular for
signet-ring histology.
Prior work has predicted that innovative concepts over-
coming pharmacologic limitations of intraperitoneal chemo-
therapy could improve, perhaps dramatically, its efficacy.26
While PIPAC remains in its infancy, the pharmacological su-
periority of this drug delivery system over systemic delivery
Fig. 2 Fifty-one years old female patient after R1 gastrectomy,
postoperative chemotherapy (FLOT), and radiochemotherapy (5-FU)
for GC, intestinal type, pT3 pN2 pM1 (per). Videolaparoscopy (a1) and
CT scan (a2) at PIPAC#1 showing multiple small bowel involvement
(white arrows) and radiological diffuse small bowel thickening (red
arrows). At PIPAC # 4, videolaparoscopy shows a complete
macroscopic response (b1) and CT a complete radiological response
according to RECIST 1.1 criteria (b2). Number sign: micropump placed
into the abdomen during laparoscopy. Asterisk: local peritonectomy scar.
Multiple biopsies confirm major remission with extensive fibrosis and
isolated vital tumor cells. Patient was alive 148 days after 1st PIPAC
with a KI of 90 %
Fig. 3 Kaplan-Meier survival curve of 24 consecutive patients after
PIPAC salvage therapy with cisplatin and doxorubicin. x-axis: survival
in months; y-axis: cumulative survival. Green line: patients with
peritoneal carcinomatosis (PC) plus other metastases. Blue line: patients
with PC without other metastases
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and conventional intraperitoneal chemotherapy for treating
peritoneal metastasis is already clear,11–13 inducing high re-
sponse rates with low adverse events.15,16
We now report on the first results obtained with PIPAC
with low-dose cisplatin and doxorubicin in patients with
chemotherapy-resistant gastric peritoneal metastasis. Objec-
tive tumor response was documented in half of the patients
after PIPAC, including complete histological regression in 6
patients. These findings confirm and extend those obtained in
ovarian (reviewed in28) and colorectal29 cancer. The present
results obtained in gastric cancer deliver further evidence sug-
gesting that PIPAC can induce regression of platinum-
resistant peritoneal metastasis in several cancer types and
might meet the clinical need for new and better therapies for
a fatal cancer.
However, in the present study, the 17 patients able to un-
dergo more than one PIPAC procedure were indeed the pa-
tients who remained alive, presumably because their tumors
responded to the first PIPAC. This is a selection bias, and it is
therefore not a surprise that the majority of these patients had a
favorable pathologic response. Thus, the response rate above
should not be extrapolated to all treated patients, and these
numbers have now to be confirmed in a prospective compar-
ative study.
Intraperitoneal chemotherapy is hampered by dose-depen-
dant, local toxicity. Local toxicity of PIPACwas acceptable, in
spite of the high tissue drug concentration and of repeated
delivery. No patient developed bowel perforation, and no se-
vere gastrointestinal symptoms were registered. These results
are in accordance with those reported in ovarian cancer, where
gastrointestinal symptoms even improved slightly under
PIPAC therapy.16
The systemic inflammatory response to the chemical peri-
tonitis following intraperitoneal chemotherapy caused few
general symptoms. In contrast to systemic chemotherapy, we
did not observe typical side effects such as alopecia, neurotoxi-
city, cardiac toxicity, and myelosuppression. In accordance
with previous observations,14–16,29 no significant renal toxicity
was documented. This appears reasonable bearing in mind the
90 % dose reduction as compared to systemic chemotherapy.
However, PIPAC induced transient low-grade liver toxicity in
a quarter of patients, as reported earlier in ovarian cancer.16
Survival data are encouraging with a median survival of
15.4 months after first PIPAC application, confirming previ-
ous observations in ovarian peritoneal metastasis with a 1-year
survival of 50 % in the third-line situation,16 and in
colorectal cancer with a median survival of 15.7 months
in the salvage situation.29 As an exception, gastric can-
cer patients with synchronous malignant pleural effusion
did not benefit from PIPAC. Two patients with terminal
disease and reduced condition (ECOG 3 and 4) died in
the hospital after the procedure, suggesting that PIPAC
is not helpful anymore in end-stage disease..
At this stage, it is not possible to define indications and
contraindications for PIPAC. However, based on our prelim-
inary experience, following observations are possible that
might help to define inclusion and exclusion criteria for future
studies: Since PIPAC can overcome platinum resistance, at
least in some patients, it is expected to become a component
of therapy of peritoneal metastasis. Time window for PIPAC
appears to open when tumor nodes become resistant to
platinum-based chemotherapy and to close when therapy-
resistant ascites or bowel obstruction develops or when gen-
eral condition deteriorates beyond ECOG 2. PIPAC might be
indicated for older patients30 and for patients who experienced
severe side effects from previous systemic chemotherapy, in-
cluding chronic renal failure and cardiac toxicity. PIPAC has
probably no clinical benefit in patients with malignant pleural
effusion of gastric origin.
Our results provide first evidence that low-dose PIPAC
therapy might be effective in treating patients with recurrent,
platinum-resistant gastric peritoneal metastasis, including the
aggressive signet-ring histology. PIPAC is well tolerated, a
decisive characteristic in this palliative setting. However, these
results are preliminary and should be interpreted conservative-
ly. Due to the framework conditions (off-label use program
without predefined inclusion and exclusion criteria), the pa-
tient cohort was heterogeneous. Thus, these results cannot be
extrapolated to all patients with gastric peritoneal metastasis.
Future work includes a prospective, regulatory phase-2
clinical trial (NCT01854255) in the salvage situation. Further
research is needed to determine if PIPAC might be indicated
as a neo-adjuvant, additive, or adjuvant therapy in gastric
cancer.
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